Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12504746 | 0.93 | ESR2 (0.36) | SMN1; SMN2BCL2L1MCL1 | |
| SCHEMBL12412839 | 0.92 | SMN1; SMN2 (0.32) | SMN1; SMN2BCL2L1MCL1 | |
| SCHEMBL12412975 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1GAABCL2L1MCL1 | |
| SCHEMBL12503777 | 0.85 | ESR2 (0.36) | SMN1; SMN2BCL2L1MCL1 | |
| SCHEMBL12412891 | 0.84 | — | — | |
| SCHEMBL12412893 | 0.83 | — | — | |
| SCHEMBL12412895 | 0.83 | MAOB (0.30) | — | |
| SCHEMBL12412954 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1GAAHPGDBCL2L1 | |
| SCHEMBL12412886 | 0.81 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1GAABCL2L1MCL1 | |
| SCHEMBL12503793 | 0.81 | ESR1 (0.36) | SMN1; SMN2ALDH1A1GAABCL2L1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166362-A1 | NOVEL COMPOUND AND ORGANIC SEMICONDUCTOR MATERIAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166362-A1 | NOVEL COMPOUND AND ORGANIC SEMICONDUCTOR MATERIAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166362-A1 | NOVEL COMPOUND AND ORGANIC SEMICONDUCTOR MATERIAL | SCLY, MSRB3, SOD1 | SMN1; SMN2 2484/4885ALDH1A1 2760/4885GAA 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.